(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of -0.04% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Viatris's revenue in 2025 is $14,330,200,000.On average, 3 Wall Street analysts forecast VTRS's revenue for 2025 to be $16,252,298,091,730, with the lowest VTRS revenue forecast at $16,100,921,286,741, and the highest VTRS revenue forecast at $16,455,995,291,310. On average, 3 Wall Street analysts forecast VTRS's revenue for 2026 to be $16,568,621,812,576, with the lowest VTRS revenue forecast at $16,407,017,542,952, and the highest VTRS revenue forecast at $16,757,209,030,551.
In 2027, VTRS is forecast to generate $16,780,865,764,217 in revenue, with the lowest revenue forecast at $16,723,090,095,858 and the highest revenue forecast at $16,889,377,356,517.